LakeShore Biopharma Co Ltd
LSB0.627USD
0.0000.00%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
13.02MMarktkapitalisierung
--KGV TTM
mehr Informationen über LakeShore Biopharma Co Ltd Unternehmen
LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
LakeShore Biopharma Co Ltd Informationen
BörsenkürzelLSB
Name des UnternehmensLakeShore Biopharma Co Ltd
IPO-datumJul 30, 2021
CEOMr. Dave Chenn
Anzahl der mitarbeiter573
WertpapierartOrdinary Share
GeschäftsjahresendeJul 30
AddresseBuilding No. 2, 38 Yongda Road
StadtBEIJING
BörseNASDAQ Capital Market Consolidated
LandChina
Postleitzahl102629
Telefon
Websitehttps://www.ysbiopharm.com/
BörsenkürzelLSB
IPO-datumJul 30, 2021
CEOMr. Dave Chenn
Führungskräfte von LakeShore Biopharma Co Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Mr. Gang Li
Mr. Gang Li
Head of Marketing and sales
Head of Marketing and sales
--
--
Dr. Stanley Yi Chang
Dr. Stanley Yi Chang
Independent Director
Independent Director
--
--
Dr. Ajit Shetty
Dr. Ajit Shetty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Thomas Xue
Mr. Thomas Xue
Director
Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Crystal Peak Investment Inc
51.01%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
Oceanpine Capital
1.12%
Shao (Hui)
0.76%
Andere
11.33%
Aktionäre
Aktionäre
Anteil
Crystal Peak Investment Inc
51.01%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
Oceanpine Capital
1.12%
Shao (Hui)
0.76%
Andere
11.33%
Aktionärstypen
Aktionäre
Anteil
Corporation
75.75%
Individual Investor
12.67%
Investment Advisor
1.18%
Private Equity
0.27%
Investment Advisor/Hedge Fund
0.07%
Andere
10.05%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
19
631.21K
1.53%
-1.57M
2025Q3
20
323.47K
0.78%
-1.42M
2025Q2
28
16.97M
69.54%
+11.06M
2025Q1
32
16.97M
88.94%
+11.13M
2024Q4
63
15.91M
83.38%
+8.88M
2024Q3
69
15.84M
83.04%
+8.47M
2024Q2
74
16.03M
84.03%
+8.50M
2024Q1
78
15.49M
82.30%
+7.79M
2023Q4
79
6.05M
65.03%
-1.81M
2023Q3
78
6.62M
71.14%
+3.69M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Crystal Peak Investment Inc
21.02M
51.01%
--
--
Nov 04, 2025
Apex Prospect Ltd
9.84M
23.87%
+1.00
+0.00%
Jul 11, 2025
Zhang (Yi)
4.91M
11.91%
--
--
Jun 30, 2025
Oceanpine Capital
462.76K
1.12%
--
--
Nov 04, 2025
Shao (Hui)
313.64K
0.76%
--
--
Jun 30, 2025
Adjuvant Capital LP
290.30K
0.7%
--
--
Nov 04, 2025
MSA Capital
112.90K
0.27%
--
--
Nov 04, 2025
Epiphron Capital (Hong Kong) Ltd
70.08K
0.17%
--
--
Nov 04, 2025
Superstring Capital Management LP
30.79K
0.07%
--
--
Nov 04, 2025
Barclays Bank PLC
24.76K
0.06%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
